NB
Neurocrine Biosciences Inc
🇺🇸XNAS.NBIXUnited StatesHealthcare
$156.71USDup +1.19 (+0.77%)OpenEnd of day3:28 PM
Price$156.71+1.19 (+0.77%)
Profile
- Healthcare
- Drug Manufacturers - Specialty & Generic
- United States
Identity
- Exchange
- Nasdaq . XNAS
- Type
- Stock
- ISIN
- US64125C1099
- CUSIP
- 64125C109
Company
- Employees
- 2,500
- Headquarters
- San Diego, United States
- Website
- https://www.neurocrine.com
- CEO
- Mr. Kyle W. Gano Ph.D.
Market
- Shares outstanding
- 101.6M
- Market cap
- $15.76B
Key dates
- Next earnings
- Oct 27, 2026
Highlights
- Market cap
- $15.76B
- EPS LTM
- $6.94calculatedCalculated by Finzer, not reported by the data provider.
- P/E LTM
- 22.58calculatedCalculated by Finzer, not reported by the data provider.
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- $3.37B+34.42%up year on year
- Net income
- $705.5M+102.56%up year on year
- Gross margin
- 97.97%-0.54%down year on year
- Free cash flow
- $870.4M+64.63%up year on year
Other listings
These are the venues Finzer covers, not every venue that exists.
Business summary
No company summary reported yet.